Lite Coat Aspirin (aspirin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Aspirin (the prototype of the salicylates) is a nonsteroidal anti-inflammatory agent (NSAIA) and also exhibits antithrombotic, analgesic, and antipyretic activity.
Aspirin is used extensively in the treatment of mild to moderate pain, fever, and inflammatory diseases. Aspirin is also used in the prevention of arterial and venous thrombosis. Aspirin, however, should be used with extreme caution, if at all, in patients in whom urticaria, angioedema, bronchospasm, severe rhinitis, or shock is precipitated by other salicylates or other NSAIAs. (See Cautions: Sensitivity Reactions in the Salicylates General Statement 28:08.04.24.)
Generic name: aspirin
Pronunciation: (AS-pir-in)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Lite Coat Aspirin
Indications
The following indications are listed for Lite Coat Aspirin:
- Acute Coronary Syndrome
- Acute Myocardial Infarction
- Acute Thromboembolic Stroke
- Cerebral Thromboembolism Prevention
- Dysmenorrhea
- Fever
- Headache Disorder
- Juvenile Idiopathic Arthritis
- Myocardial Infarction Prevention
- Myocardial Reinfarction Prevention
- Osteoarthritis
- Pain
- Prevention Of Transient Ischemic Attack
- Rheumatoid Arthritis
- Thrombosis Prevention After Percutaneous Coronary Intervention
- Transient Cerebral Ischemia
- Unstable Angina Pectoris
Also known as: Acute Cerebral Infarction Due To Thromboembolism, Acute Mi, Acute Mi Prophylaxis, Acute Myocardial Infarction Prophylaxis, Ami Prophylaxis, Arthritis Deformans, Arthrosis Deformans, Cardiac Infarct Prophylaxis, Cardiac Infarction, Cardiac Infarction Prophylaxis, Cephalgia, Cephalodynia, Crescendo Angina, Degenerative Arthritis, Degenerative Joint Disease, Degenerative Polyarthritis, Difficult Menses, Difficult Menstruation, Febrile, Febrile Reaction, Hypertrophic Arthritis, Juvenile Ra, Juvenile Rheumatoid Arthritis, Maintenance Therapy Of Thrombosis Prevention After Pci, Mi Prophylaxis, Myocardial Infarct, Myocardial Infarct Prophylaxis, Myocardial Infarction Prophylaxis, Myocardial Reinfarction Prophylaxis, Nodose Rheumatism, Osteoarthrosis, Painful Menses, Painful Menstrual Cramps, Preinfarction Syndrome, Pyrexia, Rheumatic Arthritis, Rheumatic Gout, Stroke Thromboembolism Prophylaxis, Thrombosis Prophylaxis After Percutaneous Coronary Intervention, Tia Prophylaxis, Tias Prophylaxis, Transient Ischemic Attack Prophylaxis, Transient Ischemic Attacks, Unstable Angina, Vascular Thrombosis Prevention After Percutaneous Coronary Intervention.
Dosing
Dosage of aspirin must be carefully adjusted according to individual requirements and response, using the lowest possible effective dosage. When used at high (e.g., anti-inflammatory) dosages, the development of tinnitus can be used as a sign of elevated serum salicylate concentrations, except in patients with high-frequency hearing impairment.
When preparations containing aspirin in fixed combination with other drugs are used, the cautions, precautions, and contraindications applicable to each ingredient must be considered.
Aspirin is usually administered orally, preferably with food or a large quantity (240 mL) of water (unless the patient is fluid restricted) or milk to minimize gastric irritation. In patients unable to take or retain oral medication, aspirin suppositories may be administered rectally; however, rectal absorption may be slow and incomplete. (See Pharmacokinetics: Absorption.) Aspirin tablets should not be administered rectally, since they are likely to cause irritation and erosion of the rectal mucosa. Aspirin preparations should not be used if a strong vinegar-like odor is present. (See Chemistry and Stability: Stability.)
If an unpleasant taste or aftertaste, burning in the throat, or difficulty in swallowing occurs with uncoated aspirin-containing tablets, these effects may be reduced with film-coated tablets. Although specific data are not available, these effects are also likely to be reduced with enteric-coated tablets. If gastric irritation and/or symptomatic GI disturbances occur with uncoated aspirin-containing tablets, these effects may be reduced with enteric-coated tablets or extended-release tablets. If a liquid dosage form of aspirin is desired for short-term treatment of pain, an oral solution may be prepared from commercially available effervescent tablets (e.g., Alka-Seltzer(R)) by dissolving tablets in 120 mL of water; ingest the entire solution to ensure adequate dosing.
In addition to potentially reducing adverse GI effects, some clinicians suggest that enteric-coated tablets may be swallowed more easily by children receiving chronic therapy with the drug and may therefore result in increased compliance.
Aspirin or buffered aspirin preparations should not be chewed before swallowing for at least 7 days following tonsillectomy or oral surgery because of possible injury to oral tissues from prolonged contact with aspirin particles. In addition, aspirin or buffered aspirin tablets should not be placed directly on a tooth or gum surface because of possible injury to tissues.
Capsules containing the fixed combination of aspirin and extended-release dipyridamole should be swallowed whole and should not be chewed.
Chewable aspirin tablets may be chewed, crushed, and/or dissolved in a liquid, or swallowed whole, followed by approximately 120 mL of water, milk, or fruit juice immediately after administration of the drug.
For information on the concomitant administration of aspirin with nonsteroidal anti-inflammatory agents (NSAIAs), see Drug Interactions: Nonsteroidal Anti-inflammatory Agents, in the Salicylates General Statement 28:08.04.24.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.